LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Elenco Azioni・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Chiusa

SettoreSettore sanitario

27.56 -3.7

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

26.91

Massimo

28.62

Metriche Chiave
By Trading Economics
Entrata	8.1M -31M
Vendite	35M 308M
Margine di Profitto	-10.06
Dipendenti	2,900
EBITDA	25M -7.7M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+95.45% upside

Dividendi
By Dow Jones
Utili prossimi	10 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1.2B 4.7B
Apertura precedente	31.26
Chiusura precedente	27.56

Notizie sul Sentiment di mercato

By Acuity

50%

155 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

30.5 / 33.91 Supporto e resistenza

Legend Biotech Corp ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mag 2026, 11:01 UTC

Utili

Legend Biotech 1Q Loss/Shr 15c >LEGN

25 mar 2026, 17:10 UTC

Acquisizioni, Fusioni, Takeovers

Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets -- Barrons.com

10 mar 2026, 11:01 UTC

Utili

Legend Biotech 4Q Adj EPS 1c >LEGN

10 mar 2026, 11:01 UTC

Utili

Legend Biotech 4Q Loss/Shr 8c >LEGN

10 mar 2026, 11:00 UTC

Utili

Legend Biotech 4Q Research and Development Expenses $101.3M >LEGN

10 mar 2026, 11:00 UTC

Utili

Legend Biotech 4Q Rev $306.3M >LEGN

12 nov 2025, 12:10 UTC

Utili

Legend Biotech 3Q Adj Loss $18.8M >LEGN

12 nov 2025, 12:01 UTC

Utili

Legend Biotech 3Q Loss/Shr 11c >LEGN

12 nov 2025, 12:00 UTC

Utili

Legend Biotech 3Q Rev $272.3M >LEGN

11 ago 2025, 11:06 UTC

Utili

Legend Biotech 2Q Loss/Shr 34c >LEGN

11 ago 2025, 11:06 UTC

Utili

Legend Biotech 2Q Loss $125.4M >LEGN

11 ago 2025, 11:00 UTC

Utili

Legend Biotech 2Q Rev $255.1M >LEGN

Confronto tra pari

Modifica del prezzo

Legend Biotech Corp ADR Previsione

Obiettivo di Prezzo

By TipRanks

95.45% in crescita

Previsioni per 12 mesi

Media 55.9 USD 95.45%

Alto 80 USD

Basso 29 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Legend Biotech Corp ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Legend Biotech Corp ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.5 / 33.91Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

155 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.